Tissue Regenix issues OrthoPureT XT update

Tissue Regenix Group said the early clinical data provided to support the CE mark application for OrthoPure XT (porcine tendon) has shown results highlighting the clinical relevance of the product.

The outcomes at 6 months post-operation showed a statistically significant improvement when compared to the current gold standard treatment which uses the patients' hamstring tendons or patellar tendon (autograft).

The launch of OrthoPure XT remains on track for H1 2017, with CE mark approval in the same period.

The first distribution agreements within Europe have been signed, indicators of the strong commercial and clinical support for OrthoPure XT, in preparation for rapid commercialisation in key European markets once approval is granted.